Answers are grounded in this paper and cite their sources.
Retrospective study evaluates clinical traits, treatment responses, and Ki-67's prognostic impact in differentiated thyroid carcinoma.
Objective: The 2022 WHO classification introduced differentiated high-grade thyroid carcinoma (DHGTC) as a distinct category characterized by high-grade features despite maintained differentiation. Therefore, this study aims to evaluate its clinical characteristics, treatment responses, and the prognostic impact of the Ki-67 proliferation index in this patient population. Methods: We retrospectively reviewed 3100 patients with differentiated thyroid carcinoma (DTC) between 2017 and 2024. From this baseline pool, a total of 56 patients (1.8%) were identified and re-classified as DHGTC based on mitotic count (≥5/2 mm2) and/or tumor necrosis. Additionally, 69 DTC patients (2.2%) with an elevated Ki-67 index (>5%) identified from the same baseline pool—representing an overlapping group with the DHGTC cohort—were analyzed to evaluate its clinical significance. Results: In the DHGTC group, tumor necrosis was present in 87.5% and high mitotic activity in 19.6% of cases. While all DHGTC patients were classified as high-risk under 2025 American Thyroid Association (ATA) guidelines, 42.8% showed biochemical or structural incomplete response at the last follow-up and 28.6% required additional salvage interventions. In the broader DTC cohort, Ki-67 ≥ 15% was significantly associated with older age, larger tumor size, extensive invasion, and poorer treatment response (p < 0.05). However, within the DHGTC subset, Ki-67 ≥ 15% was only significantly associated with increased lymphovascular invasion and more extensive surgery. Conclusions: DHGTC carries a significant burden of aggressive histopathological features and a high risk of structural disease persistence or recurrence. While an elevated Ki-67 index (≥15%) serves as an adverse marker in general DTC, its additional prognostic value within the high-grade DHGTC cohort remains inconclusive, potentially obscured by limited statistical power due to small subgroup sizes.
No takes yet. Share an insight, caveat, or question.
Karaahmetli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: